236 related articles for article (PubMed ID: 27213997)
1. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
Aaltonen KJ; Turunen JH; Sokka T; Puolakka K; Valleala H
Clin Exp Rheumatol; 2016; 34(4):694-7. PubMed ID: 27213997
[TBL] [Abstract][Full Text] [Related]
2. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
3. Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence.
Théate N; Geoffroy M; Kanagaratnam L; Gozalo C; Charlot I; Bolko L; Hittinger-Roux A; Djerada Z; Salmon JH
RMD Open; 2024 May; 10(2):. PubMed ID: 38772677
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
Nash P; Nicholls D
Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
7. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
[TBL] [Abstract][Full Text] [Related]
8. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.
Calvo-Alén J; Monteagudo I; Salvador G; Vázquez-Rodríguez TR; Tovar-Beltrán JV; Vela P; Maceiras F; Bustabad S; Román-Ivorra JA; Díaz-Miguel C; Rosas J; Raya E; Carmona L; Cea-Calvo L; Arteaga MJ; Fernández S; Marras C
Clin Exp Rheumatol; 2017; 35(3):423-430. PubMed ID: 28032846
[TBL] [Abstract][Full Text] [Related]
9. Determinants of methotrexate adherence in rheumatoid arthritis patients.
De Cuyper E; De Gucht V; Maes S; Van Camp Y; De Clerck LS
Clin Rheumatol; 2016 May; 35(5):1335-9. PubMed ID: 26781783
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
11. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
12. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients.
López-Medina C; Moltó A; Gérald F; Dubremetz M; Grange L; Thibaud G; Charles B; Lafarge D; Beauvais C; Gossec L; Dougados M
Joint Bone Spine; 2019 Oct; 86(5):610-614. PubMed ID: 30738192
[TBL] [Abstract][Full Text] [Related]
14. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
[TBL] [Abstract][Full Text] [Related]
15. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Agarwal S; Zaman T; Handa R
Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
[TBL] [Abstract][Full Text] [Related]
16. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
[TBL] [Abstract][Full Text] [Related]
17. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
Kristensen LE; Saxne T; Nilsson JA; Geborek P
Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
[TBL] [Abstract][Full Text] [Related]
18. The BeSt way of withdrawing biologic agents.
Allaart CF; Lems WF; Huizinga TW
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
[TBL] [Abstract][Full Text] [Related]
19. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.
Moura CS; Abrahamowicz M; Beauchamp ME; Lacaille D; Wang Y; Boire G; Fortin PR; Bessette L; Bombardier C; Widdifield J; Hanly JG; Feldman D; Maksymowych W; Peschken C; Barnabe C; Edworthy S; Bernatsky S;
Arthritis Res Ther; 2015 Aug; 17(1):197. PubMed ID: 26235697
[TBL] [Abstract][Full Text] [Related]
20. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
